NexTrial.ai

What is Trial Activation Intelligence?

Trial Activation Intelligence (TAI) is the intelligence layer that makes clinical trial startup predictable. It spans from protocol finalization to First Patient In, encompassing protocol intelligence, regulatory orchestration, site readiness validation, and predictive activation timelines. TAI compresses the typical 120-day activation timeline to 30-45 days with audit-ready documentation.

How much do clinical trial delays cost?

Clinical trial activation delays cost sponsors approximately $55,000 per day in direct costs, with enrollment burn rates of $600,000 to $1.2 million per month. The average trial takes 120 days from protocol to First Patient In, with 25-30% of regulatory submissions rejected on first attempt.

What is the zero-rejection architecture?

NexTrial's zero-rejection architecture validates regulatory packets against jurisdiction-specific requirements before submission, achieving a 94% first-submission approval rate compared to the industry average of 70-75%. Every document is audit-ready with traceable lineage.

What regulatory jurisdictions does NexTrial support?

NexTrial currently supports FDA (United States), ANVISA (Brazil), and CDSCO (India) with jurisdiction-specific regulatory intelligence. Each jurisdiction has its own Country Blueprint encoding local requirements, documentation standards, and approval pathways.

How does NexTrial work with CROs?

NexTrial offers white-label Trial Activation Intelligence for CROs. Celina appears as the CRO's own intelligence layer to sponsors — their brand, their client relationship, NexTrial's engine underneath. This protects CRO margins by compressing activation timelines and reducing coordinator burden by 7.5 hours per week.